Westmoreland Manor: Psychotropic Drug Consent Failure - PA
The facility failed to document advance notification to the family before increasing the psychotropic drug dose for the resident with dementia and anxiety, according to an April inspection report.
Resident 19 had severe cognitive impairment and received multiple psychotropic medications affecting her mental state, emotions and behavior. Her diagnoses included anxiety and dementia, and she was already taking antidepressant, antianxiety and antipsychotic medications.
On August 11, 2025, at 11:34 a.m., a Certified Registered Nurse Practitioner assessed the resident and obtained new orders to increase her clonazepam dose to 1 milligram twice daily. The medication, also known by the brand name Klonopin, was prescribed to be given before morning and evening care for anxiety and agitation.
The increase doubled her previous dose.
Inspectors found no evidence in the resident's clinical record that her representative was informed in advance about the medication change. Federal regulations require facilities to notify residents or their representatives about the risks and benefits of psychotropic medications and available treatment alternatives before starting or increasing such drugs.
When interviewed on April 8, 2026, the Clinical Compliance Certified Registered Nurse Practitioner confirmed the documentation gap. She acknowledged there was no recorded evidence that the resident's representative received advance notification about the increased Klonopin dose, its risks and benefits, or alternative treatments.
The violation affected one of 55 residents reviewed during the inspection, which found minimal harm or potential for actual harm.
Clonazepam belongs to a class of drugs called benzodiazepines, which can cause drowsiness, confusion, and increased fall risk, particularly concerning for elderly residents with dementia. The medication can also lead to physical dependence and withdrawal symptoms if stopped abruptly.
For residents with severe cognitive impairment like Resident 19, family members or designated representatives typically make healthcare decisions and must be informed about medication changes. The requirement ensures families can weigh treatment options and potential side effects when making decisions for vulnerable residents who cannot advocate for themselves.
The facility's failure to document this crucial communication represents a breakdown in the informed consent process. Without proper notification, representatives cannot make informed decisions about their loved one's psychiatric medications or request alternative treatments.
Psychotropic medications are heavily regulated in nursing homes due to their potential for overuse as chemical restraints. Federal guidelines require facilities to demonstrate that such medications are necessary for specific psychiatric conditions rather than convenience or behavioral control.
The inspection found that Westmoreland Manor violated multiple Pennsylvania regulations governing licensee responsibility, management practices, and resident rights. These state codes work in conjunction with federal nursing home standards to protect residents from inappropriate medication practices.
Resident 19's case illustrates broader concerns about medication management in long-term care facilities. When staff increase powerful psychiatric drugs without proper family consultation, it undermines the collaborative approach needed for appropriate dementia care.
The January 2026 quarterly assessment confirmed the resident continued receiving multiple psychotropic medications months after the undocumented dose increase. This ongoing treatment occurred without evidence that her representative had been consulted about the medication intensification or its continued necessity.
The violation occurred despite the facility having clinical compliance staff specifically responsible for ensuring proper medication protocols. The nurse practitioner's confirmation of the documentation failure suggests systemic gaps in the facility's informed consent procedures for psychotropic drug changes.
For families with relatives in nursing homes, the case underscores the importance of staying informed about medication changes and asking specific questions about new prescriptions or dose adjustments. Representatives have the right to receive detailed information about psychiatric medications before such treatments begin or intensify.
The inspection was completed on April 9, 2026, with the facility required to submit a plan of correction addressing the informed consent deficiency.
Full Inspection Report
The details above represent a summary of key findings. View the complete inspection report for Westmoreland Manor from 2026-04-09 including all violations, facility responses, and corrective action plans.
Additional Resources
Data source: Official federal inspection data from the Centers for Medicare & Medicaid Services (CMS).
Editorial process: AI-synthesized regulatory data, reviewed for accuracy by our editorial team.
Professional review: All content reviewed by Christopher F. Nesbitt, Sr., NH EMT & BU-trained Paralegal.
Last verified: August 4, 2026 · Our methodology
Westmoreland Manor in GREENSBURG, PA was cited for violations during a health inspection on April 9, 2026.
Resident 19 had severe cognitive impairment and received multiple psychotropic medications affecting her mental state, emotions and behavior.
Health inspections identify deficiencies that facilities must correct. Violations range from minor documentation issues to serious safety concerns. Review the full report below for specific details and facility response.